The Motley Fool··Jonathan PoncianoXenon Pharma Soars 55% on Trial Success Despite Insider Share Sale
Xenon Pharmaceuticals' CMO sold $78K in shares via routine vesting, as stock surges 55% following positive Phase 3 trial results and $750M capital raise.
XENEbiotechcapital raise